Eisai's Halaven stumbles at NICE efficacy hurdle
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, will issue preliminary draft guidance 20 July 2011 declining to recommend Eisai's Halaven (eribulin) for patients with locally advanced metastatic breast cancer whose disease has progressed after two chemotherapeutic regimens for advanced disease. NICE had originally planned to publish the guidance on 19 July but delayed publication until 20 Julybecause of confusion with Eisai over the publication date.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.